Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology Pinecast (https://pinecast.com) en-US@Point of Care @Point of Care atpointofcare@gmail.com no Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology https://storage.pinecast.net/podcasts/covers/54dff532-909d-4fc8-852b-66c58aef3572/HematologyOncology.png episodic Copyright 2020 At Point of Care, LLC. All rights reserved. https://pinecast.com/feed/oncology-point-of-care-podcast S31:E2 – Matching Therapy to Biology: The Importance of PTCL Subtype https://pinecast.com/guid/c93818c6-05f9-4d79-b0cb-6fff03c28b7b Mon, 03 Aug 2026 04:10:00 -0000 00:23:34 https://www.atpointofcare.com/library/2736.02/page/0 Given the diversity of peripheral T-cell lymphoma (PTCL) subtypes, clinicians may need guidance choosing which therapy is most appropriate for each subtype. Join Dr. Steven Horwitz and Theresa Davey, PA-C, for a discussion of the PTCL treatment landscape and the evidence for matching epigenetic therapies to specific PTCL subtypes.

Visit https://www.atpointofcare.com/library/2736.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Matching Therapy to Biology: The Importance of PTCL Subtype no 31 2 S31:E1 – Emerging Evidence: What Clinical Trials Reveal About Epigenetic Therapies in PTCL https://pinecast.com/guid/73ff7c90-99bc-4938-a16b-c69759f55648 Mon, 03 Aug 2026 04:00:00 -0000 00:26:08 https://www.atpointofcare.com/library/2736.01/page/0 Relapsed/refractory peripheral T-cell lymphoma (PTCL) remains a significant treatment challenge. Join Dr. Stephen Horwitz and Theresa Davey as they review emerging clinical trial data on epigenetic therapies, including azacitidine, HDAC (histone deacetylase) inhibitors, and EZH (enhancer of zeste homolog)-targeted agents, and discuss how biology-driven treatment strategies may help personalize care and improve outcomes for patients with PTCL.

Visit https://www.atpointofcare.com/library/2736.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Emerging Evidence: What Clinical Trials Reveal About Epigenetic Therapies in PTCL no 31 1 S31:E3 – Personalizing Care With Factor VIIIa Mimetics for Patients With Hemophilia A https://pinecast.com/guid/2f3464ec-537a-4032-918e-4c9f45dde842 Fri, 24 Jul 2026 04:10:00 -0000 00:27:04 https://www.atpointofcare.com/library/2723.02/page/0 Join expert hematologists, Drs. Stacy Croteau and Guy Young, as they provide their expert opinion regarding strategies for personalizing care for patients with hemophilia A. Topics discussed in this podcast include an overview of the current and investigational therapeutic landscape and an in-depth dialogue where they review their shared decision-making strategies and best practices for individualized care in clinical practice.

Visit [https://www.atpointofcare.com/library/2723.02/page/0 ](

This podcast is powered by Pinecast.

]]> Personalizing Care With Factor VIIIa Mimetics for Patients With Hemophilia A no 31 3 S30:E1 – Factor VIIIa Mimetics: Engineering the Future of Hemophilia A https://pinecast.com/guid/eb0965e5-6488-40d6-9715-f297ede671f2 Fri, 24 Jul 2026 04:00:00 -0000 00:29:44 https://www.atpointofcare.com/library/2723.01/page/0 Join our team of expert hematologists, Drs. Guy Young and Stacy Croteau, as they discuss factor VIIIa mimetics and their role in bleed prevention for patients with hemophilia A. Topics discussed in this podcast include an overview of current and emerging factor mimetics and an analysis of the clinical trial data of emerging factor VIIIa mimetics, denecimig and NXT007, and how these agents may change the therapeutic landscape for hemophilia A in the future.

Visit https://www.atpointofcare.com/library/2723.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Factor VIIIa Mimetics: Engineering the Future of Hemophilia A no 30 1 S29:E2 – Managing Toxicities With TROP2-Targeting ADCs for NSCLC https://pinecast.com/guid/3ac3856c-c489-4fcd-8d07-60a9e3932e47 Tue, 30 Jun 2026 04:00:00 -0000 00:29:05 https://www.atpointofcare.com/library/2730.12/page/0 In this episode, Dr. Kristen Marrone and nurse practitioner Beth Sandy discuss strategies for preventing the key adverse effects associated with datopotamab deruxtecan (Dato-DXd), including stomatitis, ocular toxicities, and drug-induced interstitial lung disease/pneumonitis.

Visit Managing Toxicities With TROP2-Targeting ADCs for NSCLC to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Managing Toxicities With TROP2-Targeting ADCs for NSCLC no 29 2 S29:E1 – TROP2 ADCs in NSCLC: Mechanisms and Management https://pinecast.com/guid/071b6d5b-cc0e-4157-a94b-6dc6c1c3accd Tue, 30 Jun 2026 04:00:00 -0000 00:33:43 https://www.atpointofcare.com/library/2730.11/page/0 In this episode, Dr. Kristen Marrone and nurse practitioner Beth Sandy discuss the mechanism and clinical evidence supporting TROP2-directed ADCs, emerging agents and combinations, and ongoing biomarker development to optimize patient selection.

Visit TROP2 ADCs in NSCLC: Mechanisms and ManTROP2 ADCs in NSCLC: Mechanisms and Managementagement to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> TROP2 ADCs in NSCLC: Mechanisms and Management no 29 1 S28:E2 – Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS https://pinecast.com/guid/a7e84695-b8bc-4972-a1b3-4b8fc2878280 Fri, 24 Apr 2026 04:10:00 -0000 00:30:20 https://suitehome.atpointofcare.com/library/2729.02/page/0 In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS they review the clinical trial and real-world evidence on the efficacy and safety of currently available therapies for patients with lower-risk myelodysplastic syndrome (LR-MDS)-associated anemia. Their thought-provoking discussion will give an overview of the pertinent publications while highlighting the clinical implications of this data, in practice. 

Visit https://suitehome.atpointofcare.com/library/2729.02/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS no 28 2 S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS https://pinecast.com/guid/24cb6932-57fd-47d5-b3be-e67072b7c8f4 Fri, 24 Apr 2026 04:00:00 -0000 00:23:28 https://suitehome.atpointofcare.com/library/2729.01/page/0 In this podcast episode, Andrew Kuykendall, MD,  and Sangeetha Venugopal, MD, MS explore dose escalation strategies for the erythroid maturation agent (EMA), luspatercept, in patients with lower-risk myelodysplastic syndrome (LR-MDS). Their engaging discussion will give an overview of the pertinent clinical trial efficacy and safety data and recent changes to the prescribing information, as well as delving into how they both apply this information in their clinical practices.

Visit https://suitehome.atpointofcare.com/library/2729.01/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn

]]> Clearing the Confusion on Dosing for Luspatercept in LR-MDS no 28 1 S27:E3 – Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs https://pinecast.com/guid/ae08b184-ecaf-45c3-aef8-9fab9f25587d Thu, 15 Jan 2026 05:20:00 -0000 00:30:38 https://suitehome.atpointofcare.com/library/2720.03/page/0 In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Discussion will include why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC, quantitative continuous scoring (QCS) as a predictive biomarker, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated adverse events (AEs). 

Visit https://suitehome.atpointofcare.com/library/2720.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs no 27 3 S27:E2 – TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib https://pinecast.com/guid/94a22bad-9e2d-49dd-b748-79cd70218e39 Thu, 15 Jan 2026 05:10:00 -0000 00:28:36 https://suitehome.atpointofcare.com/library/2720.02/page/0 In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. Their discussion will include: 1) why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC; 2) quantitative continuous scoring (QCS) as a predictive biomarker; 3) current efficacy and safety data from clinical trials; and 4) best practices for monitoring and mitigating ADC-associated toxicities. 

Visit https://suitehome.atpointofcare.com/library/2720.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib no 27 2